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A turn-on competitive immunoassay using a low-cost Blu-ray optomagnetic setup and two differently
sized magnetic particles (micron-sized particles acting as capture particles and nano-sized particles
acting as detection particles) is here presented. For Salmonella detection, a limit of detection of
8104 CFU/mL is achieved within a total assay time of 3 h. The combination of a competitive strategy
and an optomagnetic setup not only enables a turn-on read-out format, but also results in a sensitivity
limit about a factor of 20 times lower than of volumetric magnetic stray ﬁeld detection device based
immunoassays. The improvement of sensitivity is enabled by the formation of immuno-magnetic ag-
gregates providing steric hindrance protecting the interior binding sites from interaction with the
magnetic nanoparticle labels. The formation of immuno-magnetic aggregates is conﬁrmed by ﬂuores-
cence microscopy. The system exhibits no visible cross-reaction with other common pathogenic bacteria,
even at concentrations as high as 107 CFU/mL. Furthermore, we present results when using the setup for
a qualitative and homogeneous biplex immunoassay of Escherichia coli and Salmonella typhimurium.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The development of sensitive assays for identiﬁcation and de-
tection of microorganisms is vital for improving diagnosis and
preventing disease outbreaks. These assays also play essential
roles in control programs provided by food-safety regulatory
agencies and disease control and prevention agencies (Swami-
nathan and Feng, 1994; Hood et al., 2004; Virgin and Todd, 2011).
Many of the latest generation devices, such as surface plasmon
resonance (SPR) sensors (Zeng et al., 2014), nuclear magnetic re-
sonance (NMR) devices (Harel et al., 2008), and surface enhanced
Raman scattering (SERS) spectrometers (Han et al., 2009), are re-
garded as promising biosensor setups that have been commer-
cialized to a large extent in order to meet the requirements of the
society. Unfortunately, the relatively high cost and complexity
associated with many of today's diagnostic assay platforms limit
their ability to contribute to sustainable health care systems in
developing countries (Urdea et al., 2006). To address this problem,
the research community has turned to nanoscale labels, e.g. col-
loidal gold nanoparticles (Giljohann et al., 2010), quantum dots
(Medintz et al., 2005) and magnetic nanoparticles (Haun et al.,
2010; Canfarotta and Piletsky, 2014) in the search for user-friendly
and inexpensive diagnostic tools that can be used in remote areasr B.V. This is an open access articl
e (M. Strömberg).where sophisticated lab facilities are not available (Kelley et al.,
2014; Brandao et al., 2015).
The last decade has yielded breakthroughs within the devel-
opment of nano-/microparticle based biosensors, in which the
afﬁnity capture is effectively achieved by coating dispersed nano-
or microparticles with capture molecules (Gu et al., 2006; Tekin
and Gijs, 2013). Due to their ability to be easily manipulated by
magnetic ﬁeld gradients and the negligible magnetic background
of biological objects, superparamagnetic particles have been in-
creasingly used as labels in volumetric assays (Borlido et al., 2013;
Issadore et al., 2014). In biosensing platforms based on the de-
tection of the presence or absence of magnetic particle labeled
targets, the read-out is performed in various magnetic stray ﬁeld
detection devices, measuring changes in either static or dynamic
properties of the magnetic particles upon interaction with the
target, such as magnetoresistance sensors (Baselt et al., 1998;
Graham et al., 2003; Dalslet et al., 2011), Hall effect devices (Mi-
hajlovic et al., 2005; Sandhu et al., 2007; Østerberg et al., 2014),
magnetic tunnel junctions (Grancharov et al., 2005), super-
conducting quantum interference devices (Chemla et al., 2000;
Grossman et al., 2004; Strömberg et al., 2008), or AC suscept-
ometers (Astalan et al., 2004; Park et al., 2011; Zardán Gómez de la
Torre et al., 2011). On the one hand, by employing enzymatic
ampliﬁcation strategies for improving the sensitivity, those mag-
netic biosensors are capable of detecting nucleic acid targets with
a limit of detection (LOD) in the low pM range (Dalslet et al., 2011;
Østerberg et al., 2014; Strömberg et al., 2008; Zardán Gómez de lae under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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afﬁnity capture strategy, e.g. a bacterial immunoassay, the sensi-
tivity of those devices (LOD of higher than 106 CFU/mL) is inferior
compared to that of a miniaturized nuclear magnetic resonance
(NMR) system (LOD of 103 CFU/mL), which beneﬁts from a built-in
signal ampliﬁcation (since millions of water molecules can be af-
fected by one individual magnetic particle) (Grossman et al., 2004;
Chen et al., 2015). Furthermore, all those aforementioned bio-
sensors require expensive instrumentation.
An alternative option for magnetic particle labeled target de-
tection is to make use of optomagnetic (magneto-optic) sensor
systems, which measure a modulation of an optical signal related
to the Brownian relaxation dynamics of magnetic particles (Aurich
et al., 2007; Chung et al., 2008; Donolato et al., 2015a). Although
the optomagnetic devices have provided signiﬁcant reductions in
instrumentation cost, their performance regarding magnetic par-
ticle labeled target detection is similar to the magnetic stray ﬁeld
detection systems discussed above. Chung et al. (2008) estimated
that the minimum detectable number of MNPs for their opto-
magnetic setup was 107. Aurich et al. (2007) employed a similar
optomagnetic system and a homogeneous immunoassay strategy
to detection human eotaxin and human IgG, and the LOD was
found to be 1 nM and 70 pM, respectively. So far, optomagnetic
sensors have not been reported for the detection of bacteria or
cells. In addition, to the best of our knowledge, all reported volu-
metric magnetic stray ﬁeld detection devices and optomagnetic
device based immunoassays have employed direct immunoassay
strategies, which means that they are negative (turn-off) assays,
implying that it can be difﬁcult to judge whether the reduction in
sensor signal is due to poor assay performance or the presence of
target (van Lierop et al., 2011).
Here, we present a novel Salmonella detection methodology
using a low-cost Blu-ray optomagnetic setup. The utilization of a
competitive turn-on immunoassay strategy associated with two
kinds of magnetic particles (5 μm and 100 nm magnetic particles)
gives a LOD of 8104 CFU/mL within a total assay time of 3 h.
Similar bioassay methods have been reported by Donolato et al.
(2015a, 2015b) and Bejhed et al. (2015) for DNA detection, but this
is the ﬁrst time that the Blu-ray optomagnetic sensor is reported
for a turn-on immunoassay strategy. In this work, for the com-
petitive immunoassay scheme, bacteria are afﬁnity captured by
biotinylated-antibody coated 5 μm magnetic particles (Ab-MPs) to
form immuno-magnetic aggregates. For certain bacterial con-
centrations, large immuno-magnetic aggregates are formed, i.e.
clusters of capture MPs and bacteria. Thereafter, the aggregates are
incubated with streptavidin-coated 100 nm magnetic nano-
particles (MNPs). Finally, the unreacted (non-bound) MNPs in the
suspension are detected by the Blu-ray optomagnetic setup. The
existence of immuno-magnetic aggregates containing clusters of
Ab-MPs is conﬁrmed using ﬂuorescence microscopy. Furthermore,
the competitive strategy is compared with a direct immunoassay
scheme involving direct binding of Ab-conjugated 100 nm MNPs
to bacteria, which shows that the competitive strategy is about 20
times more sensitive. Finally, we present a homogeneous and bi-
plex detection strategy for Salmonella typhimurium and Escher-
ichia coli. In the biplex detection, E. coli directly binds to Ab-
250 nm detection MNPs, i.e. a direct detection strategy, while si-
multaneously S. typhimurium binds to the Ab-MPs to form im-
muno-magnetic aggregates (thereby preventing binding of detec-
tion streptavidin-100 nm MNPs to Ab-MPs), i.e. a competitive
strategy. In addition, it is worth mentioning that the cost of this
read-out system is very low in comparison to other devices, e.g.
only a few percent of the cost for a miniaturized NMR device
(about 50,000€).2. Experimental section
2.1. Reagents and bacterial strains
Ultrapure grade phosphate buffered saline (PBS, 20 ) was
purchased from AMRESCO (Solon, USA) and was diluted to 1
before being used as the incubation/reaction/washing buffer and
blank control sample. Biotinylated rabbit anti Salmonella group
(biotinylated polyclonal antibody, with 6–8 biotin groups per an-
tibody according to the manufacturer) and rabbit anti E. coli
(polyclonal antibody) were purchased from AbD Serotec. Avidin
modiﬁed 5 μm MPs (product code 08-18-503), streptavidin mod-
iﬁed 100 nm MNPs (product code 10-19-102) and protein A
modiﬁed 250 nm MNPs (product code 09-20-252) were purchased
from Micromod (Rostock, Germany). Biotin (5-ﬂuorescein) con-
jugate was purchased from Sigma-Aldrich and dissolved in DMSO
(purchased from Sigma). Heat-killed S. typhimurium cells (Catalog
No. 50-74-01, KPL, Gaithersburg, USA) were used as the positive
control sample. Enterococcus faecalis (CCUG 9997), E. coli (CCUG
17620), Staphylococcus aureus (CCUG 17621), Proteus mirabilis
(CCUG 26767) and Klebsiella oxytoca (CCUG 42935) were obtained
from the Department of Medical Sciences, Clinical Microbiology
and Infectious Medicine, Uppsala University. All bacteria were
suspended in PBS and stored at 4 °C.
2.2. Conjugation of magnetic particles and magnetic nanoparticles
with antibodies
For the competitive immunoassay, polyclonal antibodies were
conjugated to avidin-coated MPs (to obtain capture particles, here
denoted Ab-MPs) by mixing biotinylated rabbit anti Salmonella
group antibody (4 mg/mL) and 5 μm MPs (25 mg/mL,
3.5108 particles/mL) in a volumetric ratio of 1:2 followed by
incubation at 37 °C for 2 h to perform the avidin–biotin reaction.
After washing two times using a magnetic separation stand, the
Ab-MPs were resuspended at a concentration of 25 mg/mL
(3.5108 particles/mL) in PBS.
For the direct immunoassay, antibody-conjugated 100 nm
MNPs were prepared by mixing biotinylated rabbit anti Salmonella
group Ab (4 mg/mL) and 100 nm streptavidin-coated MNPs
(10 mg/mL) in a volumetric ratio of 3:4 followed by incubation at
37 °C for 2 h. After washing two times, the Ab-MNPs were re-
suspended at a concentration of 10 mg/mL in PBS.
For the biplex assay, detection MNPs for E. coli were prepared
by mixing anti E. coli Ab (4 mg/mL) and protein A modiﬁed 250 nm
MNPs (10 mg/mL) in a volumetric ratio of 3:4 followed by in-
cubation at 37 °C for 2 h and resuspended at a concentration of
10 mg/mL.
Ab-MPs and Ab-MNPs were stored at 4 °C for further use.
2.3. Competitive immunoassay for Salmonella
The competitive immunoassay consisted of three independent
steps: capture, labeling and detection (see Scheme 1). First, the
sample (blank, positive or negative) was mixed with Ab-MPs and
incubated at 37 °C for 1.5 h. The mixture was shaken every 20 min
to avoid sedimentation. After incubation and magnetic separation,
the immuno-magnetic aggregates were washed once and re-
suspended (keeping the volume unchanged) in PBS. Thereafter
streptavidin modiﬁed 100 nm magnetic nanoparticles, serving as
detection particles, were added and the ﬁnal concentration of
MNPs was about 0.1 mg/mL. The MNPs were incubated with the
immuno-magnetic aggregates at 37 °C for 1 h. After this step,
65 μL of the suspension was transferred into an UV-transparent
disposable cuvette (REF 67.758.001, SARSTEDT, Nümbrecht, Ger-
many). In order to let the immuno-magnetic aggregates sediment
Scheme 1. Schematic illustration of the Blu-ray optomagnetic measurement based
competitive immunoassay for S. typhimurium detection. The assay consists of three
independent steps (from left to right in the illustration): capture, labelling and
detection. Capture: 5 mm-sized magnetic particles equipped with biotinylated
polyclonal antibody against Salmonella are added to the sample, positive (top row)
or blank (bottom row) and incubated. Labelling: Streptavidin modiﬁed 100 nm
magnetic nanoparticles, serving as detection nanoparticles, are added followed by
incubation. Detection: The suspension is transferred into a cuvette and the im-
muno-magnetic clusters are left to sediment to the bottom of the cuvette prior to
performing target quantiﬁcation in a Blu-ray optomagnetic system.
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sured optomagnetic response, the cuvette was left on the bench
for 20 min prior to optomagnetic read-out.
2.4. Optomagnetic measurement setup
A detailed description is provided in Supplementary Material,
section S1. The output from one measurement (used for target
quantiﬁcation) is the total intensity of transmitted laser light, V0,
the in-phase, V2′ , and the out-of-phase, V2″, components of the
complex second harmonic signal of the transmitted light. In the
competitive immunoassay approach, V2′ was normalized with re-
spect to the simultaneously measured value of V0 to compensate
for the variations in laser light intensity, particle concentration and
cuvette reﬂection/absorption. In the direct immunoassay and
homogeneous biplex immunoassay, V2′ was directly employed as
the output signal for target quantiﬁcation since V0 was signiﬁcantly
inﬂuenced by the concentration of bacteria in the cuvette. Mea-
surements of V2′ and V0 at room temperature were performed in
the frequency range 10–10,000 Hz, using an AC magnetic excita-
tion ﬁeld amplitude of 2.6 mT.Fig. 1. Panel A: Peak value of V V/2 0′ vs. labelling time normalized with respect to the pea
the curves represent pure MNP sample, [MPs (no antibody)þMNPs] sample, [Ab-MP
respectively. Panel B: V V/2 0′ spectra measured for a labelling time of 60 min.2.5. Fluorescence microscopy study of the immuno-magnetic
aggregations
A detailed description is provided in Supplementary Material,
section S2. Immuno-magnetic aggregates were incubated ﬁrst
with MNPs and thereafter with biotin (5-ﬂuorescein) conjugates,
and studied in a ﬂuorescence microscope (Axioplan II, Zeiss).
2.6. Homogeneous biplex immunoassay for S. typhimurium and E.
coli
A detailed description is provided in Supplementary Material,
section S3. Two different kinds of antibody conjugated magnetic
particles were added to the sample and incubated. After incuba-
tion, the immuno-magnetic aggregates were reacted with MNPs
and detected by the optomagnetic read-out.3. Results and discussion
3.1. Establishment of the competitive immunoassay
Scheme 1 shows the principle behind the competitive im-
munoassay. In summary, if S. typhimurium cells and/or fragments
are suspended in the sample, these entities will react with the
biotinylated antibodies on the surface of the MPs and sterically
prevent these antibodies from interacting with the subsequently
added detection nanoparticles (streptavidin MNPs). If no bacteria
are present, a part of the streptavidin MNPs will attach to the Ab-
MPs by the streptavidin-biotin reaction, causing the peak value of
V V/2 0′ to be smaller than for a bacteria containing sample. The peak
amplitude can therefore be used for qualitative detection of S. ty-
phimurium in the sample.
To evaluate the kinetics of the competitive immunoassay, Ab-
MPs of 2106 particles/mL were incubated with a positive control
sample (S. typhimurium of 107 CFU/mL) and a blank control sample
(PBS) at 37 °C for 1.5 h (as a capture step). After washing, strep-
tavidin modiﬁed MNPs were added to the suspensions to a ﬁnal
concentration of 0.1 mg/mL (as a labelling step). Thereafter V2′ and
V0 were recorded as a function of labelling time (cf. Fig. 1A). As
shown in Fig. 1B, the frequency dependence of V V/2 0′ is closely
related to the Brownian relaxation dynamics of the MNPs andk value of V V/2 0′ measured at 0 min for a pure MNP suspension. From top to bottom,
sþpositive controlþMNPs] sample and [Ab-MPsþblank controlþMNPs] sample,
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of the pure MNP suspension ((V V/2 0′ )max, MNPs, 0 min) was chosen as
a reference value for normalizing the peak values of the other
samples. From the results shown in Fig. 1A, it can be seen that
(V V/2 0′ )max decreases with increasing labelling time. For the pure
MNP sample, the decrease is due to the fact that a small amount of
MNPs adheres to the inner wall of the EP tube, thus not con-
tributing to the modulation of the transmitted light. The peak
value of the [MPs (no antibody)þMNPs] sample is slightly lower
than that of the pure MNP sample. We attribute such features to
inter-assay variations and/or to magnetic interaction ﬁelds due to
MPs sediment, which attract MNPs to the bottom of the cuvette
and prevent them from contributing to the measured optomag-
netic response. For the [Ab-MPsþpositive controlþMNPs] and
[Ab-MPsþblank controlþMNPs] samples, the peak decrease is
mainly related to the speciﬁc (biotin–streptavidin) and nonspeciﬁc
(bacterial surface-streptavidin) bindings of MNPs to immuno-
magnetic aggregates. To maintain a balance between the total la-
belling time and signal-to-noise ratio, 60 min was chosen as the
reaction time of the labelling step.Fig. 2. Panel A: Peak value of V V/2 0′ vs. Ab-MP concentration. Panels B, C and D sho
concentration of 1.25105, 5105, 2106 particles/mL, respectively. Note that the peak
blank controls. Error bars indicate one standard deviation based on three independent m
samples.3.2. Qualitative detection of S. typhimurium
For the competitive immunoassay strategy (Scheme 1), it can
be concluded that the amount of Ab-MPs used to capture the
bacteria is strongly correlated to the sensitivity and speciﬁcity of
the system. On the one hand, the smaller amount of Ab-MPs used,
the fewer bacteria are needed to block the biotinylated antibodies
from interaction with the subsequently added streptavidin MNPs,
and thus the lower the LOD will be. On the other hand, the smaller
amounts of Ab-MPs used, the fewer MNPs can bind to MPs, and
thus the lower the signal-to-noise ratio will be. To optimize the
amount of Ab-MPs, a series of Ab-MP concentrations (from 2103
to 2106 particles/mL) was chosen for reacting with 0.1 mg/mL
streptavidin MNPs, and a cut-off value was calculated as the
average of (V V/2 0′ )max for a triplicate measurement using a blank
control sample (PBS) minus three times the standard deviation of
the triplicate (Fig. 2A). Although the dose-response curve indicates
that the smallest concentration below the cut-off value (red da-
shed line) was 3104 particles/mL, the signal-to-noise ratio for
this amount of Ab-MPs was too low to be used for furtherw peak value of V V/2 0′ vs. S. typhimurium concentration when using an Ab-MP
values in panels B–D have been normalized with respect to the peak values of the
easurements. Dashed lines indicate the cut-off value calculated from blank control
B. Tian et al. / Biosensors and Bioelectronics 77 (2016) 32–3936experiments. The coefﬁcients of variation for each point of the
curve shown in Fig. 2A were less than 4.8%.
A concentration series of S. typhimurium was measured using
the competitive immunoassay. The immunoassay was performed
using Ab-MP concentrations of 1.25105, 5105 and
2106 particles/mL, and the results of those measurements are
shown in Fig. 2B–D, respectively. Normalized peak values of the
blank controls (( V V/2 0′ )max, Blank Control) were used not only to
calculate the cut-off values (average signal for a triplicate mea-
surement plus three times the standard deviation of the triplicate)
for each experiment, but also to normalize the signals to com-
pensate for the inter-assay variations. As mentioned earlier, the
LOD for S. typhimurium improves upon decreasing the amount of
Ab-MPs, and the best LOD 8104 CFU/mL was achieved for an Ab-
MP concentration of 1.25105 particles/mL (Fig. 2B). Interestingly,
the smallest measured S. typhimurium concentration above the
cut-off value corresponded well with the concentration of Ab-MPs
used, implying that large immuno-magnetic aggregates were ef-
ﬁciently formed when having a MP/bacteria ratio of 1:1. The
coefﬁcients of variation for each point of the curves shown in
Fig. 2B–D were less than 3.7%, 5.4% and 6.7% respectively.
The shape of the dose-response curves in Fig. 2B–D is governed
mainly by two mechanisms: (1) formation of immuno-magnetic
aggregates containing clusters of Ab-MPs, providing steric hin-
drance preventing streptavidin-MNPs from binding to biotinylated
antibodies inside clusters; and (2) saturation of Ab-MPs by bac-
teria, which prevents direct binding of streptavidin-MNPs to Ab-
MPs. Immuno-magnetic aggregates containing clusters of Ab-MPs
form below a certain bacterial concentration limit, which depends
on the concentration of MPs (around 1:1 ratio of MP/bacteria). The
Ab-MP cluster size increases with increasing bacterial concentra-
tion up to this limit, which results in an increasing dose-response
curve. Above this limit the aggregates containing several Ab-MPs
no longer form, and the immuno-magnetic aggregates mainly
contain single Ab-MP. At even higher bacterial concentrations,
more and more bacteria bind to the surfaces of Ab-MPs, yielding aFig. 3. Representative ﬂuorescence photomicrographs of MPs after reaction with the ind
used in these experiments.dose-response increasing with bacterial concentration and even-
tually to a plateau in the curve when the Ab-MPs become satu-
rated with bacteria. We thus infer that the sudden decrease of
signal between the peak and the plateau represents a situation
where aggregates containing clusters of Ab-MPs cannot form, but
instead the immuno-magnetic aggregates appear as single Ab-MPs
with only a few bound bacteria each, thus having free binding sites
for MNPs.
In another test described in Supplementary Material, section
S4, the Ab-MPs/bacteria incubation time was shortened to 0.5 h to
investigate its inﬂuence on the sensitivity of the assay. In the
measurement employing 5105 particles/mL Ab-MPs, the sensi-
tivity was not signiﬁcantly affected by the smaller incubation time
compared with the dose-response curve in Fig. 2C. To balance the
sensitivity and stability, subsequent competitive immunoassay
tests were performed using an Ab-MPs concentration of
5105 particles/mL.
3.3. Fluorescence microscopy study of Ab-MP/bacteria binding
The ﬂuorescence photomicrographs (Fig. 3) conﬁrm the ex-
istence of immuno-magnetic aggregates containing clusters of Ab-
MPs and also show that the formation of such immuno-magnetic
aggregates mainly exists below a certain bacterial concentration
limit. It should be mentioned that the small biotin (5-ﬂuorescein)
molecule can easily diffuse into the interior of the immuno-mag-
netic aggregations and bind to both free avidin groups on the MPs
and to free streptavidin groups on the MNPs. This enables easy and
straightforward visualization of free Ab-MPs and immuno-mag-
netic aggregations in a ﬂuorescence microscope.
In this study, Ab-MPs with a concentration of
5105 particles/mL were reacted with samples containing differ-
ent concentrations of bacteria. Because of steric hindrance, bioti-
nylated antibodies cannot block all the biotin binding sites on the
surface of avidin-MPs, implying that the bacteria–Ab-MPs con-
jugates can still be labeled by the biotin (5-ﬂuorescein) conjugate.icated S. typhimurium samples. An Ab-MP concentration of 5105 particles/mL was
Fig. 4. Speciﬁcity study of the competitive immunoassay. Common pathogenic
bacteria at a concentration of 107 CFU/mL in PBS were investigated. The con-
centration of Ab-MPs was 5105 particles/mL. Error bars indicate one standard
deviation based on three independent measurements.
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107 CFU/mL), Ab-MPs were covered by excessive bacterial frag-
ments and could, thus, not form aggregates containing clusters of
Ab-MPs (Fig. 3A). This in turn resulted in that only a few MNPs
(with bound ﬂuorescent labels) were bound to the Ab-MPs, in
accordance with the observed plateau at the position of
107 CFU/mL in Fig. 2C. As the concentration ratio of bacteria/Ab-
MPs was reduced, non-saturated immuno-magnetic aggregates
containing single Ab-MPs coexisting with a few aggregates con-
taining small clusters of Ab-MPs were observed (Fig. 3B), but these
immuno-magnetic aggregates cannot sterically block the binding
sites for MNPs, in accordance with the valley at the position of
2106 CFU/mL in Fig. 2C. Immuno-magnetic aggregates contain-
ing large clusters of Ab-MPs (Fig. 3C) create steric hindrance
around the interior binding sites which reduces the amount of
bound streptavidin MNPs, thus giving rise to a peak around
106 CFU/mL S. typhimurium in Fig. 2C. In Fig. 3D, Ab-MPs were still
free after being incubated with the blank control sample (PBS),
and the ﬂuorescence intensity was slightly higher than for the MPs
in the other images. This observation can be explained by the fact
that in this case a large number of MNPs (with ﬂuorescent labels
on surface) were attached to the Ab-MPs.
3.4. Comparison of competitive and direct immunoassay strategies
By using the same reagents and read-out device, a direct im-
munoassay strategy for S. typhimurium detection was evaluated
and compared with the competitive assay approach (details are
given in Supplementary Material, section S5). The LOD for the
direct immunoassay was found to be approximately
2106 CFU/mL (cf. Fig. S4), which corroborates previous results
(5.6106 CFU/mL) reported by Grossman et al. (2004). A dynamic
range of at least two orders of magnitude is obtained for the direct
immunoassay strategy. A competitive immunoassay is generally
less sensitive than the corresponding direct assay, but in this study
it was proven to be more sensitive. This could be explained by the
fact that the amount of biotin binding sites on the surface of the
Ab-MPs is much larger and easier to control than the amount of
antigen sites on the surface of typical bacteria. In addition, the
formation of immuno-magnetic aggregates containing clusters of
Ab-MPs strongly reduces the number of available binding sites,
thus further enhancing the sensitivity. In the direct immunoassay
strategy, immuno-magnetic aggregates could also be formed by
Ab-MNPs and bacteria. (Wang et al., 2015) However, cross-linking
between Ab-MNPs and bacteria means that the bacteria are not
saturated with Ab-MNPs (bacteria are sharing the labels), and
hence, the sensitivity is limited. If we regard the 5 μm Ab-MPs as
“ideal bacteria” with target molecules covering their entire sur-
face, the LOD of a direct immunoassay for this “bacteria” would be
3104 particles/mL, which can be appreciated by inspection of
Fig. 2A. Since it is nearly impossible to achieve such an ideal si-
tuation in real clinical tests, the competitive assay strategy per-
forms better than the direct immunoassay strategy. This can be
explained by the fact that the strength of antibody–antigen in-
teraction (employed in the direct immunoassay) is variable and
not as strong as the biotin–streptavidin pair used in this compe-
titive immunoassay.
3.5. Speciﬁcity evaluation of competitive and direct immunoassays
The speciﬁcity (selectivity) of the competitive and direct im-
munoassay approaches was investigated by considering ﬁve types
of other common pathogenic bacteria (see Section 2.1) as negative
controls (at 107 CFU/mL and 108 CFU/mL, respectively). Results
presented in Fig. 4 show that the normalized peak values,
(V V/2 0′ )max/(V V/2 0′ )max, Blank Control, of the negative control samplesare close to 1, meaning that the response from the negative con-
trols are similar to the blank control. Similar results were obtained
for the direct immunoassay strategy (see Fig. S5), indicating that
no signiﬁcant amounts of bacteria other than S. typhimurium were
captured by the Ab-MPs (in competitive immunoassay) or Ab-
MNPs (in direct immunoassay). Therefore, the current approaches
were able to differentiate S. typhimurium from other clinical
common pathogenic bacteria and are therefore suitable for the
speciﬁc detection of S. typhimurium.
3.6. Homogeneous biplex immunoassay for S. typhimurium and
E. coli
This optomagnetic setup can be used for multiplex detection,
since MNPs with different hydrodynamic sizes have V 2′ peak/val-
ley values at different frequencies. The V 2′ valley (negative peak) of
250 nm MNPs is located at 18 Hz, while the V 2′ peak of 100 nm
MNPs is located at 184 Hz. Direct and competitive immunoassays
were employed for E. coli and S. typhimurium using 250 nm and
100 nm MNPs as detection labels, respectively. As shown in
Fig. 5A, each spectrum has its own signature in terms of valley/
peak values and frequency positions. For the spectra of the E. coli
containing samples, i.e., the yellow triangles and blue diamonds,
the absolute values of the valley at 14–18 Hz are smaller than for
the blank sample (red squares), since a fraction of the Ab-250 nm
MNPs are bound to the E. coli. When measuring the spectra of
S. typhimurium containing samples, the black circles and blue
diamonds, the Salmonella fragments covered the Ab-MPs and left
more streptavidin-100 nm MNPs free in the suspension, resulting
in higher peak values at 184 Hz. In view of the homogeneous bi-
plex immunoassay results (Fig. 5B), we conclude that the setup can
be applied for qualitative multiplex immunoassays.4. Conclusion
In summary, we have presented a turn-on competitive im-
munoassay using a low-cost Blu-ray optomagnetic setup for read-
out. This qualitative detection strategy utilizes two differently
Fig. 5. Panel A: Average V 2′ spectra of three independent measurements measured for a homogeneous biplex immunoassay. Direct and competitive immunoassays were
employed for E. coli and S. typhimurium using 250 nm and 100 nm MNPs as detection labels, respectively. The optomagnetic response of free Ab-250 nm MNPs and
streptavidin-100 nm MNPs was characterized by a valley/peak at 18 Hz and 184 Hz, respectively. E: 107 CFU/mL E. coli; S: 107 CFU/mL S. typhimurium. 0: absence of bacteria.
Panel B: Bar graph showing the value of V 2′ at the frequency of 18 Hz and 184 Hz. Error bars indicate one standard deviation based on three independent measurements.
B. Tian et al. / Biosensors and Bioelectronics 77 (2016) 32–3938sized magnetic particles and gives a LOD of 8104 CFU/mL S. ty-
phimurium within a total assay time of 3 h. The improvement of
the sensitivity was achieved by the formation of immuno-mag-
netic aggregates containing clusters of Ab-MPs providing steric
hindrance protecting the interior binding sites from interaction
with the magnetic nanoparticle labels. The existence of immuno-
magnetic aggregates containing clusters of Ab-MPs was conﬁrmed
by ﬂuorescence microscopy. This presented method is fully com-
patible with a large variety of pathogens and can be used for the
detection of urinary tract samples, which have a high positive CFU
threshold (usually 105 CFU/mL) (Mezger et al., 2015). Moreover,
our method can be easily combined with the use of a MP pre-
treatment procedure to enrich the bacteria before the test, thereby
further improving the LOD. The immunoassay exhibits no visible
cross-reaction with other clinically common pathogenic bacteria,
even at a concentration of 107 CFU/mL. If a positive answer is
obtained from the qualitative competitive assay, we can further
quantify the bacterial concentration by employing a direct im-
munoassay approach. Furthermore, we have demonstrated a
qualitative and homogeneous biplex immunoassay of E. coli and
S. typhimurium. In consideration of the advantages shown in this
study, as well as the low-cost of the setup, the system has a great
potential to be used for cost-efﬁcient and user-friendly identiﬁ-
cation and detection of microorganisms relating to e.g. food safety.Acknowledgments
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